Home › Research › Treatments
Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T.. Neurobiology of aging, 2009-11-17
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
To test the effects of the PPAR-γ agonist pioglitazone on cognition, regional cerebral blood flow (rCBF), and plasma levels of Aβ40 and Aβ42, we conducted a 6-month, randomized, open-controlled trial in patients with mild Alzheimer disease (AD) accompanied with type II diabetes mellitus. We randomly assigned 42 patients to either the group treated with 15-30 mg pioglitazone daily (n=21, pioglitazone group) or not (n=21, control group). The pioglitazone group improved cognition and rCBF in the parietal lobe, while the control group showed no such improvement. The plasma Aβ40/Aβ42 ratio increased in the control group, but showed no significant change in the pioglitazone group. Both groups showed good control of diabetes during the study. In addition, pioglitazone treatment resulted in a decrease in fasting plasma insulin levels, indicating enhanced insulin sensitivity. The results of this pilot study demonstrated that pioglitazone exhibited cognitive and functional improvements, and stabilization of the disease in diabetic patients with AD. Pioglitazone may offer a novel strategy for the treatment of AD.
What this study adds
Evidence grade: High
This is a trial of 21 participants. In this small pilot trial of 42 patients with mild Alzheimer disease and type II diabetes, those given pioglitazone showed cognitive and functional improvements and stabilization of the disease. Because it was a pilot study, these results need confirmation in larger trials.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011). Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiology of aging. https://doi.org/10.1016/j.neurobiolaging.2009.10.009
Vancouver
Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease. Neurobiology of aging. 2011. doi:10.1016/j.neurobiolaging.2009.10.009. PMID: 19923038.
BibTeX
@article{sato2011-19923038,
author = {Sato, T. and Hanyu, H. and Hirao, K. and Kanetaka, H. and Sakurai, H. and Iwamoto, T.},
title = {{Efficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease}},
journal = {Neurobiology of aging},
year = {2011},
doi = {10.1016/j.neurobiolaging.2009.10.009},
pmid = {19923038},
url = {https://doi.org/10.1016/j.neurobiolaging.2009.10.009}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The plasma Aβ40/Aβ42 ratio increased in the control group, but showed no significant change in the pioglitazone group.
- The results of this pilot study demonstrated that pioglitazone exhibited cognitive and functional improvements, and stabilization of the disease in diabetic patients with AD.
Why it matters
In this small pilot trial of 42 patients with mild Alzheimer disease and type II diabetes, those given pioglitazone showed cognitive and functional improvements and stabilization of the disease. Because it was a pilot study, these results need confirmation in larger trials.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants21
- Evidence strengthHigh
How this study scored 69/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 44 of the 64 points we could judge it on, which is 69 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurobiology of aging) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2011 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 21 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | — / 7 | No citation count (OpenAlex dates this DOI to 2009, the record says 2011; OpenAlex values not used) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 3 / 6 | Cited by 12 other studies in this library |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 19923038) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 44 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 44 of the 64 points we could judge it on is 69 out of 100. |
| Total | 69 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall and Europe PMC found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
12 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.